Table 1

Clinical activity of camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer

Objective response
 No. of response20
 % of patients (95% CI)54 (38 to 69)
Disease control
 No. of disease control33
 % of patients (95% CI)89 (77 to 96)
Best overall response—no. (%)
 Complete response0 (0)
 Partial response20 (54)
 Stable disease13 (35)
 Progression disease3 (8)
 No assessment*1 (3)
Time to response—months
Duration of response—months
  • *One patient discontinued before the first postbaseline radiographic assessment because of a treatment-related adverse event.